

Current and Emerging Therapies for **FOLLICULAR LYMPHOMA:** Solving Practice Challenges in Community-Based Interprofessional Care Teams

Reference List

- Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: Lymphoid neoplasms. *Leukemia*. 2022;36(7):1720-1748. doi:10.1038/s41375-022-01620-2
- Ardeshna KM, Qian W, Smith P, et al. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. *Lancet Oncol*. 2014;15(4):424-435. doi:10.1016/S1470-2045(14)70027-0
- Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. *J Clin Oncol*. 1998;16(8):2780-2795. doi:10.1200/JCO.1998.16.8.2780
- Barracough A, Bishton M, Cheah CY, Villa D, Hawkes EA. The diagnostic and therapeutic challenges of Grade 3B follicular lymphoma. *Br J Haematol*. 2021;195(1):15-24. doi:10.1111/bjh.17404
- Bartlett NL, Sehn LH, Matasar MJ, et al. Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable safety profile in patients with relapsed/refractory follicular lymphoma who received ≥ 2 prior therapies: Updated results from a pivotal phase II study. *Blood*. 2022;140(Suppl 1):1467-1470. doi:10.1182/blood-2022-157691
- Beaupierre A, Kahle N, Lundberg R, Patterson A. Educating multidisciplinary care teams, patients, and caregivers on CAR T-cell therapy. *J Adv Pract Oncol*. 2019;10(Suppl 3):29-40. doi:10.6004/jadpro.2019.10.4.12
- Béguelin W, Popovic R, Teater M, et al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. *Cancer Cell*. 2013;23(5):677-692. doi:10.1016/j.ccr.2013.04.011
- Bödör C, Grossmann V, Popov N, et al. EZH2 mutations are frequent and represent an early event in follicular lymphoma. *Blood*. 2013;122(18):3165-3168. doi:10.1182/blood-2013-04-496893
- Bou Zeid N, Yazbeck V. PI3k inhibitors in NHL and CLL: An unfulfilled promise. *Blood Lymphat Cancer*. 2023;13:1-12. doi:10.2147/BLCTT.S309171
- Budde LE, Assouline S, Sehn LH, et al. Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: Phase I dose-escalation study. *J Clin Oncol*. 2022;40(5):481-491. doi:10.1200/JCO.21.00931
- Budde LE, Sehn LH, Matasar M, et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. *Lancet Oncol*. 2022;23(8):1055-1065. doi:10.1016/S1470-2045(22)00335-7
- Campo E, Jaffe ES, Cook JR, et al. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. *Blood*. 2022;140(11):1229-1253. doi:10.1182/blood.2022019016

Current and Emerging Therapies for **FOLLICULAR LYMPHOMA:** Solving Practice Challenges in Community-Based Interprofessional Care Teams

- Carrasco-Padilla C, Hernaiz-Esteban A, Álvarez-Vallina L, Aguilar-Sopeña O, Roda-Navarro P. Bispecific antibody format and the organization of immunological synapses in T cell-redirecting strategies for cancer immunotherapy. *Pharmaceutics*. 2023; 15(1):132. doi:10.3390/pharmaceutics15010132
- Casulo C, Barr PM. How I treat early-relapsing follicular lymphoma. *Blood*. 2019;133(14):1540-1547. doi:10.1182/blood-2018-08-822148
- Casulo C, Dixon JG, Le-Rademacher J, et al. Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials. *Blood*. 2022;139(11):1684-1693. doi:10.1182/blood.2020010263
- Dreyling M, Dickinson M, Lopez JM, et al. Long-term clinical outcomes and correlative efficacy analyses in patients (pts) with relapsed/refractory follicular lymphoma (r/r FL) treated with tisagenlecleucel in the Elara trial. *Blood*. 2022;140(Suppl 1):1459-1463. doi:10.1182/blood-2022-158024
- Dreyling M, Ghielmini M, Rule S, et al. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2021;32(3):298-308. doi:10.1016/j.annonc.2020.11.008
- Dreyling M, Santoro A, Mollica L, et al. Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study. *Am J Hematol*. 2020;95(4):362-371. doi:10.1002/ajh.25711
- Dreyling MH, Santoro A, Leppä S, et al. Six-year safety and efficacy results from the CHRONOS-1 study of the PI3K inhibitor copanlisib in patients with relapsed or refractory follicular lymphoma. *J Clin Oncol*. 2023;41(Suppl 16):7555-7555. doi:10.1200/JCO.2023.41.16_suppl.7555
- Falchi L, Abrisqueta P, Nijland M, et al. Subcutaneous epcoritamab with rituximab + lenalidomide in patients with relapsed or refractory follicular lymphoma: Phase 1/2 trial update. *Blood*. 2022;140(Suppl 1):1464-1466. doi:10.1182/blood-2022-158203
- Falini B, Martino G, Lazzi S. A comparison of the International Consensus and 5th World Health Organization classifications of mature B-cell lymphomas. *Leukemia*. 2023;37(1):18-34. doi:10.1038/s41375-022-01764-1
- Fowler NH, Dickinson M, Dreyling M, et al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. *Nat Med*. 2022;28(2):325-332. doi:10.1038/s41591-021-01622-0
- Hucks G, Rheingold SR. The journey to CAR T cell therapy: the pediatric and young adult experience with relapsed or refractory B-ALL. *Blood Cancer J*. 2019;9(2):10. doi:10.1038/s41408-018-0164-6
- Hutchings M, Mous R, Clausen MR, et al. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study. *Lancet*. 2021;398(10306):1157-1169. doi:10.1016/S0140-6736(21)00889-8
- Jacobsen E. Follicular lymphoma: 2023 update on diagnosis and management. *Am J Hematol*. 2022;97(12):1638-1651. doi:10.1002/ajh.26737

Current and Emerging Therapies for FOLLICULAR LYMPHOMA: Solving Practice Challenges in Community-Based Interprofessional Care Teams

Jacobson CA, Chavez JC, Sehgal AR, et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. *Lancet Oncol.* 2022;23(1):91-103. doi:10.1016/S1470-2045(21)00591-X

Kegyes D, Constantinescu C, Vrancken L, et al. Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient? *J Hematol Oncol.* 2022;15(1):78. doi:10.1186/s13045-022-01296-2

Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. *Biol Blood Marrow Transplant.* 2019;25(4):625-638. doi:10.1016/j.bbmt.2018.12.758

Link BK, Day BM, Zhou X, et al. Second-line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study. *Br J Haematol.* 2019;184(4):660-663. doi:10.1111/bjh.15149

Marcus R, Davies A, Ando K, et al. Obinutuzumab for the first-line treatment of follicular lymphoma. *N Engl J Med.* 2017;377(14):1331-1344. doi:10.1056/NEJMoa1614598

Minson A, Dickinson M. Glofitamab CD20-TCB bispecific antibody. *Leuk Lymphoma.* 2021;62(13):3098-3108. doi:10.1080/10428194.2021.1953016

Molina JC, Shah NN. CAR T cells better than BiTEs. *Blood Adv.* 2021;5(2):602-606. doi:10.1182/bloodadvances.2020003554

Morschhauser F, Dahiya S, Palomba ML, et al. TRANSCEND FL: Phase 2 study results of lisocabtagene maraleucel (liso-cel) in patients (pts) with relapsed/refractory (R/R) follicular lymphoma (FL). *Hematol Oncol.* 2023;41(S2):877-880. doi:10.1002/hon.3196_LBA4

Morschhauser F, Fowler NH, Feugier P, et al. Rituximab plus lenalidomide in advanced untreated follicular lymphoma. *N Engl J Med.* 2018;379(10):934-947. doi:10.1056/NEJMoa1805104

Morschhauser F, Le Gouill S, Feugier P, et al. Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study. *Lancet Haematol.* 2019;6(8):e429-e437. doi:10.1016/S2352-3026(19)30089-4

Morschhauser F, Nastoupil L, Feugier P, et al. Six-year results from RELEVANCE: Lenalidomide plus rituximab (R²) versus rituximab-chemotherapy followed by rituximab maintenance in untreated advanced follicular lymphoma. *J Clin Oncol.* 2022;40(28):3239-3245. doi:10.1200/JCO.22.00843

Morschhauser F, Tilly H, Chaidos A, et al. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. *Lancet Oncol.* 2020;21(11):1433-1442. doi:10.1016/S1470-2045(20)30441-1

Nath K, Gandhi MK. Targeted treatment of follicular lymphoma. *J Pers Med.* 2021;11(2):152. doi:10.3390/jpm11020152

National Cancer Institute SEERS Program. Cancer Stat Facts: NHL-Follicular Lymphoma. Accessed November 8, 2023. <https://seer.cancer.gov/statfacts/html/follicular.html>

Current and Emerging Therapies for FOLLICULAR LYMPHOMA: Solving Practice Challenges in Community-Based Interprofessional Care Teams

National Comprehensive Cancer Network. B-Cell Lymphomas. v.6.2023. Published October 10, 2023. Accessed November 8, 2023. https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf

National Comprehensive Cancer Network. Management of Immunotherapy-Related Toxicities. v.3.2023. Published October 11, 2023. Accessed November 9, 2023. https://www.nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf

National Comprehensive Cancer Network. Prevention and Treatment of Cancer-Related Infections. Version 1.2023. Published June 28, 2023. Accessed October 4, 2023. https://www.nccn.org/professionals/physician_gls/pdf/infections.pdf

Neelapu SS, Chavez J, Sehgal AR, et al. 3-year follow-up analysis of ZUMA-5: A phase 2 study of axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma iNHL). *Blood*. 2022;140(Suppl 1):10380-10383. doi:10.1182/blood-2022-156120

Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy—assessment and management of toxicities. *Nat Rev Clin Oncol*. 2018;15(1):47-62. doi:10.1038/nrclinonc.2017.148

Nooka AK, Nabhan C, Zhou X, et al. Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices. *Ann Oncol*. 2013;24(2):441-448. doi:10.1093/annonc/mds429

Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. *Lancet*. 2013;381(9873):1203-1210. doi:10.1016/S0140-6736(12)61763-2

Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. *Blood*. 2016;127(20):2375-2390. doi:10.1182/blood-2016-01-643569

Subklewe M. BiTEs better than CAR T cells. *Blood Adv*. 2021;5(2):607-612. doi:10.1182/bloodadvances.2020001792

Taszner M, Luminari S, Cho SG, et al. P1083: Odronextamab in patients with relapsed/refractory follicular lymphoma grade 1-3A: Results from a prespecified analysis of the pivotal phase 2 study ELM-2. *Hemasphere*. 2023;7(Suppl): e214536e. doi:10.1097/01.HS9.0000971228.21453.6e

Thandra KC, Barsouk A, Saginala K, Padala SA, Barsouk A, Rawla P. Epidemiology of non-Hodgkin's lymphoma. *Med Sci (Basel)*. 2021;9(1):5. doi:10.3390/medsci9010005

Yazdy MS, Ujjani C. Current challenges in the management of follicular lymphoma. *Int J Hematol Oncol*. 2017;6(1):13-24. doi:10.2217/ijh-2017-0003

Zhu M, Olson K, Kirshner JR, et al. Translational findings for odronextamab: From preclinical research to a first-in-human study in patients with CD20+ B-cell malignancies. *Clin Transl Sci*. 2022;15(4):954-966. doi:10.1111/cts.13212